Upcoming readouts expected for experimental cardiovascular drug class
Biotech observers are awaiting crucial trial results for a novel category of heart disease drugs. The upcoming data could shape future treatment options.
Related stories
Lilly's upcoming mid-stage data puts amylin drug design under spotlight · Drug development
Eyepoint's wet AMD therapy misses key endpoint in trial · Drug development
Personalized mRNA vaccine hits Phase 3 goal in Merck-Moderna trial · Cancer research
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: Key data on a new class of cardio drugs are coming.” Browse more stories.